Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.
Pharmacogenetics of drug metabolizing enzymes and transporters: effects on pharmacokinetics and pharmacodynamics of anticancer agents.
复制标题
DOI：
10.2174/187152010794474019
复制
发表时间：
2010-10-01
影响因子：
2.8
通讯作者：
Lee NH
中科院分区：
文献类型：
--
作者：
Lee NH
大多数抗癌药物标准剂量的药物反应和毒性存在广泛的患者间差异。通常发现，抗癌药物靶向的代谢酶、受体和药物转运蛋白编码基因的遗传多态性部分是导致观察到的变异性的原因。基因中约80%的序列变异是单核苷酸多态性或SNP形式。SNP的位置可以在蛋白质编码序列、调控区或基因的外显子-内含子边界。由这些序列变异引起的药物不良反应是由于编码蛋白质的活性变化（在许多情况下，蛋白质是非功能性的）或基因表达水平的扰动。药物遗传学检测的目的是确定易使患者发生药物不良反应的遗传多态性，从而使医疗保健提供者能够就药物类型、剂量和给药时间表做出明智的决定。
There is wide interpatient variability in drug response and toxicity to standard doses of most anticancer medications. Genetic polymorphisms in genes encoding metabolic enzymes, receptors and drug transporters targeted by anticancer medications are often found, in part, to be responsible for the observed variability. Approximately 80% of all sequence variations residing in genes is in the form of single nucleotide polymorphisms or SNPs. The location of SNPs can be in the protein coding sequence, regulatory regions or at exon-intron boundaries of genes. Adverse drug reactions resulting from these sequence variations are due to changes in the activity of the encoded protein (in many instances the protein is non-functional) or perturbations in the level of gene expression. The goal of pharmacogenetic testing is to identify genetic polymorphisms that predispose patients to an adverse drug reaction, thereby allowing the health care provider to make informed decisions pertaining to the type of drug, dosage and dosage scheduling to be administered.